Prime Research

Latest Research

Drug Pipeline Update: January 2022

This monthly pipeline wrap up provides a review of newly approved drugs, recent drug launches, generic updates, new indications and news of note on drugs…

Read More

Biosimilar strategy for infliximab by MedDrive™ includes the reference drug

The U.S. Food and Drug Administration (FDA) first approved Janssen Biotech’s Remicade® (infliximab) in April of 1998 for the treatment of Crohn’s disease. It was…

Read More

February 2022 decisions expected from the FDA

At Prime Therapeutics (Prime), we’ve positioned ourselves to best prepare our clients to manage new drugs. Our clinical and trade relations teams keep a keen…

Read More
Select a Research Type
Drug pipeline updates
Prime analysis
Scientific presentations
Loading …